AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
MannKind to buy scPharmaceuticals for $5.35 per share in cash
ByAinvest
Monday, Aug 25, 2025 7:30 am ET1min read
MannKind to buy scPharmaceuticals for $5.35 per share in cash
MannKind Corporation (NASDAQ: MNKD) has announced its intention to acquire scPharmaceuticals, Inc. in a cash deal valued at $5.35 per share. The acquisition, which is expected to close in the third quarter of 2025, aims to expand MannKind's portfolio of inhaled therapeutic products and strengthen its position in the rare lung diseases market [1].The deal comes on the heels of MannKind's solid performance during the fiscal second quarter of 2025, as reported by Faisal Khurshid from Leerink Partners, who reiterated a Buy rating on the company with a price target of $7 [1]. The analyst highlighted MannKind's progress in treating idiopathic pulmonary fibrosis, nontuberculous mycobacterial lung disease, and pediatric uses of Afrezza.
The acquisition of scPharmaceuticals will enhance MannKind's capabilities in developing and commercializing inhaled therapeutic products for endocrine and rare lung diseases. This move is expected to bolster MannKind's revenue streams and solidify its market position.
The transaction will be funded through a combination of cash and debt financing. The total consideration for the acquisition is approximately $1.1 billion, which is expected to be funded through a combination of cash on hand and new debt financing.
MannKind's stock has been volatile in recent years, but the company's strong pipeline and recent quarterly results have drawn positive attention from analysts. While the acquisition of scPharmaceuticals may introduce additional risks, it also presents significant opportunities for growth.
MannKind's management has expressed optimism about the deal, noting that it aligns with the company's strategic goals and will enable it to better serve its patients and investors. The acquisition is subject to regulatory approval and other customary closing conditions.
References:
[1] https://finance.yahoo.com/news/leerink-partners-reiterates-buy-mannkind-034530254.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet